CELL LINES

Contributor Information
- Name Ghanem Elias, Ahmad Najem
- Institute Universit? libre de Bruxelles
- Primary citation Gembarska et al. 2012. Nat Med 18, 12391247. PMID: 22820643
Tool Details
- Tool name: MM029 cell line
- Tool type: Cell Line
- Parental cell line: Ham's F10 melanoma culture medium (HMCM)
- Organism: Human
- Donor: Derived from a lymph node metastasis of a female with superficial spreading melanoma (SSM)
- Tissue: Lymphatic
- Gender: Female
- Cancer type: Skin cancer
- Disease: Cancer
- Growth properties: Adherent
- Model: BRAF: V600K
- Model description: This cell line displays an invasive/Mesenchymal_like phenotype
- CRISPR: No
- Application: High-throughput screening/Drug testing - 3D cell cultures
- Description: Cell Pigmentation:Unpigmented cell line. Drug response: Intrinsic resistance to BRAFi
- Research area: Cancer
- For Research Use Only
Target Details
Application Details
- Application: High-throughput screening/Drug testing - 3D cell cultures
Handling
- Format: Frozen
- Growth medium: Hamâs F10 supplemented with 10% of fetal calf serum (FCS), with L-glutamine (1mM), penicillin (100 IU/ml), and streptomycin (100 Â?g/ml). Renewal 2 to 3 times per week
- Temperature: 37°C
- Atmosphere: 5% CO2
- Storage conditions: Liquid Nitrogen
- Shipping conditions: Dry Ice
- Initial handling information: The frozen culture should be stored in liquid nitrogen upon arrival or thaw the vial and initiate the culture as soon as possible upon receipt
- Cultured in antibiotics?: Yes
- STR profile: Cell Line Authentication was performed using STR profiling with AmpFLSTRâ? Identifilerâ? PCR Amplification Kit (Thermo Fisher Scientific). 16 independent PCR-systems (D8S1179, D21S11, D7S820, CSF1PO, D3S1358, TH01, D13S317, D16S539, D2S1338, AMEL, D5S818, FGA, D19S433, vWA, TPOX, and D18S51) were investigated and analyzed (Eurofins Genomics, Germany). The STR profile will be provided
- Biosafety level: BSL-2
- Subculture routine: Split sub-confluent cultures (70-80%) 1:2
Related Tools
References
- • Sabbah et al. 2021. Mol Cancer Res. 19(7):1221-1233. PMID: 33741716
- • Krayem et al. 2014. Eur J Cancer. 50(7):1310-20. PMID: 24559688
- • Krayem et al. 2018. Oncotarget. 9(61):31888-31903. PMID: 30159130
- • Soumoy et al. 2020. Cancers (Basel). 12(5):1323. PMID: 32455924
- • Porcelli et al. 2015. J Transl Med. 13:26. PMID: 25623468
- • Wouterset al. 2020. Nat Cell Biol. 22(8):986-998. PMID: 32753671
- • Verfaillie et al. 2015. Nat Commun 6, 6683. PMID: 25865119
- • Aftimos et al. 2013. Int J Oncol. 43(3):919-26. PMID: 23835698
- • Zannat et al. 2013. J Biol Regul Homeost Agents. 27(1):131-41. PMID: 23489693
- • Mauduit et al. 2021. eLife 10:e71735. PMID: 34874265
- • Huang et al. 2021. J Clin Invest. 131(8):e140752. PMID: 33690225